Roles of survivin isoforms in the chemopreventive actions of NSAIDS on colon cancer cells

Apoptosis

Volumn 12, Issue 6, 2007, Pages 1109-1116

  Mandayam, Sarathy ^a,b   Huang, Richard ^a,b   Tarnawski, Andrzej S ^a,b   Chiou, Shiun Kwei ^a,b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Colon cancer; NSAIDs; Survivin; Survivin isoforms

Indexed keywords

INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; SURVIVIN; SURVIVIN 2B; SURVIVIN DELTA EX3; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PREVENTION; CELL DEATH; COLON CANCER; CONTROLLED STUDY; DATA ANALYSIS; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REDUCTION; WILD TYPE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL DEATH; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; INDOMETHACIN; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN ISOFORMS; RNA, MESSENGER; TIME FACTORS;

EID: 34247874545     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-006-0011-2     Document Type: Article

References (38)

1. Mahotka C, Krieg T, Krieg A et al (2002) Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer 100:30-36
2. Rudin CM, Thompson CB (1997) Apoptosis and disease: regulation and clinical relevance of programmed cell death. Annu Rev Med 48:267-281
3. Smalley W, Ray WA, Daugherty J, Griffin MR (1999) Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population study. Arch Intern Med 159:161-166
4. Thun MJ, Nambodiri MM, Heath CW Jr (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325:1593-1596
5. Giovannucci E, Egan KM, Hunter DJ et al (1995) Aspirin and the risk of colon cancer in Women. N Engl J Med 333:609-614
6. Gega M, Yanagi H, Yoshikawa R et al (2006) Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 24:11-22
7. Phillips RK, Wallace MH, Lynch PM et al (2002) A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50:857-860
8. Steinbach G, Lynch PM, Phillips RK et al (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946-1952
9. Girardiello FM, Offerhaus JA, Tersmette AC et al (1996) Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors. Gut 38:578-581
10. Terry MB, Gammon MD, Zhang FF et al (2004) Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 291:2433-2440
11. Liu X, Slummer SJ, Nock NL, Casey G, Witte JS (2006) Non-steroidal antiinflammatory drugs and decreased risk of advanced prostate cancer: modification by lymphotoxin alpha. Am J Epidemiol. Epub ahead of print
12. Castonguay A, Rioux N, Duperron C, Jalbert G (1998) Inhibition of lung tumorigenesis by NSAIDS: a working hypothesis. Exp Lung Res 24:605-615
13. Funkhouser EM, Sharp GB (1995) Aspirin and reduced risk of esophageal carcinoma. Cancer 76:1116-1119
14. Tamm I, Wang Y, Sausville E et al (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases and anticancer drugs. Cancer Res 58:5315-5320
15. Shin S, Sung BJ, Cho YS et al (2001) An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40:1117-1123
16. Takashima H, Nakajima T, Moriguchi M et al (2005) In vivo expression patterns of survivin and its splicing variants in chronic liver disease and hepatocellular carcinoma. Liver Int 25:77-84
17. Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-921
18. Gianani R, Jarboe E, Orlicky D et al (2001) Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol 32:119-125
19. Grossman D, McNiff JM, Li F, Altieri DC (1999) Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 113:1076-1081
20. Zhang T, Otevrel T, Gao Z, Ehrlich SM, Fields JZ, Boman BM (2001) Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 61:8664-8667
21. Boman BM, Fields JZ, Bonham-Carter O, Runquist OA (2001) Computer modeling implicates stem cell overproduction in colon cancer initiation. Cancer Res 61:8408-8411
22. Ambrosini G, Adida C, Sirugo G, Altieri DC (1998) Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 273:11177-11182
23. Chen J, Wu W, Tahir SK et al (2000) Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia 2:235-241
24. Olie RA, Simoes-Wust AP, Baumann B et al (2000) A novel anti-sense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60:2805-2809
25. Zhang T, Fields JZ, Ehrlich SM, Boman BM (2004) The chemopreventive agent sulindac attenuates expression of the antiapoptotic protein survivin in colorectal carcinoma cells. J Pharmacol Exp Ther 308(2):434-437
26. Chiou SK, Tanigawa T, Akahoshi T, Abdelkarim B, Jones MK, Tarnawski AS (2005) Survivin: a novel target for indomethacin-induced gastric injury. Gastroenterology 128:63-73
27. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD (1999) Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 59:6097-6102
28. Conway EM, Pollefeyt S, Cornelissen J et al (2000) Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions. Blood 95:1435-1442
29. Noton EA, Colnaghi R, Tate S et al (2006) Molecular analysis of survivin isoforms: Evidence that alternatively spliced variants do not play a role in mitosis. J Biol Chem 281:1286-1295
30. Islam A, Kageyama H, Hashizume K, Kaneko Y, Nakagawara A (2000) Role of survivin, whose gene is mapped to 17q25, in human neuroblastoma and identification of a novel dominant-negative isoform, survivin-beta/2B. Med Pediatr Oncol 35:550-553
31. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45
32. Kato J, Kuwabara Y, Mitani M et al (2001) Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 95:92-95
33. Asanuma K, Moriai R, Yajima T et al (2000) Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 91:1204-1209
34. Krieg A, Mahotka C, Krieg T et al (2002) Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer 86:737-743
35. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N (1998) Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58:5071-5074
36. Suga K, Yamamoto T, Yamada Y, Miyatake S, Nakagawa T, Tanigawa N (2005) Correlation between transcriptional expression of survivin isoforms and clinicopathological findings in human colorectal carcinomas. Oncol Rep 13:891-897
37. Sarela AI, Macadam RC, Farmery SM, Markham AF, Guillou PJ (2000) Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46:645-650
38. Japanese society for cancer of the colon and rectum: Japanese classification of colorectal carcinoma. Kanehara Co, Tokyo 1997, pp. 3-74